Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
Key Highlights
- ➤FDA feedback supports TTI-109 Phase 2 development approach in ulcerative colitis and Crohn’s disease
- ➤Tvardi plans to submit TTI-109 IND in 2027, subject to additional funding
- ➤TTI-109 analysis supports sustained STAT3 inhibition with minimal predicted STAT1 and STAT5 effects
- ➤Phase 2 initiation remains subject to FDA IND clearance and additional funding availability
- ➤TTI-109 delivered TTI-101-equivalent exposure with improved tolerability in Phase 1 volunteers
Expert Statements
John Kauh, Chief Medical Officer of Tvardi Therapeutics
“We are pleased with the FDA’s constructive feedback, which is in line with our expectations, supports our overall approach to developing TTI-109 and gives us clear direction as we prepare our IND submission.”
John Kauh, Chief Medical Officer of Tvardi Therapeutics
“STAT3 is a central driver of immune dysregulation, inflammation and fibrosis that underlie inflammatory bowel disease.”
John Kauh, Chief Medical Officer of Tvardi Therapeutics
“Building on our positive Phase 1 results, including a new analysis supporting the potential for sustained STAT3 inhibition with minimal STAT1 and STAT5 inhibition at the proposed clinical doses, we believe TTI-109 may offer a differentiated oral treatment option for patients with inflammatory bowel disease.”
John Kauh, Chief Medical Officer of Tvardi Therapeutics
“We look forward to advancing TTI-109 into Phase 2 development, subject to IND clearance and the availability of additional funding.”
HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it has received written responses from the U.S. Food and Drug Administration (FDA) to its pre-Investigational New Drug (pre-IND) meeting request for TTI-109, the Company’s next-generation oral STAT3 inhibitor. The meeting package outlined the Company’s plans for Phase 2 development of TTI-109 in inflammatory bowel disease (IBD).
Ulcerative colitis (UC) remains the Company’s initial indication for TTI-109. In addition, Tvardi is evaluating Crohn’s disease (CD), the other major form of IBD, as a potential additional indication. STAT3 is a key signaling protein in multiple pathways involved in both UC and CD, and the Company’s STAT3 inhibitors have demonstrated activity in preclinical models of both diseases. Given this biological overlap, Tvardi sought and received FDA feedback on both UC and CD, which gives the Company the flexibility to advance the two indications either in parallel or sequentially.
Get started
Create a free account to read the full story.
